Special Issue "Targeted Prodrugs"
Deadline for manuscript submissions: 1 June 2019
Prof. William Robert Wilson
Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
Website | E-Mail
Interests: tumour hypoxia; 3D cell culture models; radiation biology; drug discovery and development; CRISPR screens
Prodrug technologies are widely used to improve systemic drug delivery, but can also be used to target drugs to specific sites. This Special Issue focuses on prodrugs of the latter type, which are designed to increase drug exposure of disease targets relative to normal tissues. This search for selectivity is a focus in cancer therapeutics in particular, but also in other diseases. Topics of relevance to this update and overview of prodrug technologies include design of compounds responsive to disease-specific triggering mechanisms (such as tumour hypoxia) and the biological evaluation of such prodrugs.Prof. William Robert Wilson
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Bystander effects
- Targeted drug delivery
- Tumor hypoxia
- Prodrug-activating enzymes